Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Nov;12(11):1317-21.
doi: 10.1128/CDLI.12.11.1317-1321.2005.

Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63

K H Chan  1 , V C C Cheng, P C Y Woo, S K P Lau, L L M Poon, Y Guan, W H Seto, K Y Yuen, J S M Peiris
Affiliations

Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63

K H Chan et al. Clin Diagn Lab Immunol. 2005 Nov.

Abstract

The serological response profile of severe acute respiratory syndrome (SARS) coronavirus (CoV) infection was defined by neutralization tests and subclass-specific immunofluorescent (IF) tests using serial sera from 20 patients. SARS CoV total immunoglobulin (Ig) (IgG, IgA, and IgM [IgGAM]) was the first antibody to be detectable. There was no difference in time to seroconversion between the patients who survived (n = 14) and those who died (n = 6). Although SARS CoV IgM was still detectable by IF tests with 8 of 11 patients at 7 months postinfection, the geometric mean titers dropped from 282 at 1 month postinfection to 19 at 7 months (P = 0.001). In contrast, neutralizing antibody and SARS CoV IgGAM and IgG antibody titers remained stable over this period. The SARS CoV antibody response was sometimes associated with an increase in preexisting IF IgG antibody titers for human coronaviruses OC43, 229E, and NL63. There was no change in IF IgG titer for virus capsid antigen from the herpesvirus that was used as an unrelated control, Epstein-Barr virus. In contrast, patients who had OC43 infections, and probably also 229E infections, without prior exposure to SARS CoV had increases of antibodies specific for the infecting virus but not for SARS CoV. There is a need for awareness of cross-reactive antibody responses between coronaviruses when interpreting IF serology.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
(A to C) Serological profile of three illustrative patients with SARS during the first month of illness. The results of a comparison of antibody titers to SARS CoV by neutralization tests and by indirect immunofluorescence tests for IgGAM, IgG, IgM, and IgA classes are shown. For some patients, IF antibody titers to OC43, 229E, and/or NL63 are also shown.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chan, K. H., J. S. Tam, J.S. Peiris, W. H. Seto, and M. H. Ng. 2001. Epstein-Barr virus (EBV) infection in infancy. J. Clin. Virol. 21:57-62. - PubMed
    1. Chan, K. H., L. L. Poon, V.C. Cheng, Y. Guan, I. F. Hung, J. Kong, L. Y. Yam, W. H. Seto, K. Y. Yuen, and J. S. Peiris. 2004. Detection of SARS coronavirus in patients with suspected SARS. Emerg. Infect. Dis. 10:294-299. - PMC - PubMed
    1. Che, X. Y., L. W. Qiu, Z. Y. Liao, Y. D. Wang, K. Wen, Y. X. Pan, W. Hao, Y. B. Mei, V. C. Cheng, and K. Y. Yuen. 2005. Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43. J. Infect. Dis. 191:2033-2037. - PMC - PubMed
    1. Drosten, C., S. Gunther, W. Preister, S. van der Werf, H. R. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, R. A. Fouchier, A. Berger, A. M. Burguiere, J. Cinatl, M. Eickmann, N. Escriou, K. Grywna, S. Kramme, J. C. Manuguerra, S. Muller, V. Rickerts, M. Sturmer, S. Vieth, H. D. Klenk, A. D. Osterhaus, H. Schmitz, and H. W. Doerr. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348:1967-1976. - PubMed
    1. Gill, E. P., E. A. Dominguez, S. B. Greenberg, R. L. Atmar, B. G. Hogue, B. D. Baxter, and R. B. Couch. 1994. Development and application of an enzyme immunoassay for coronavirus OC43 antibody in acute respiratory syndrome. J. Clin. Microbiol. 32:2372-2376. - PMC - PubMed

Publication types

Substances

LinkOut - more resources

  NODES
Association 1
twitter 2